 | • レポートコード：MRC309Z7837 • 出版社/出版日：GlobalInfoResearch / 2023年9月 • レポート形態：英文、PDF、98ページ • 納品方法：Eメール（2-3営業日） • 産業分類：医薬品＆ヘルスケア |
| Single User | ￥487,200 (USD3,480) | ▷ お問い合わせ |
| Corporate User | ￥974,400 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| GlobalInfoResearchの最新の調査によると、世界の心筋梗塞治療薬の市場規模は2022年のxxx米ドルから2029年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。新型コロナウイルス感染症とロシア・ウクライナ戦争の影響を考慮しながら市場規模を推計しました。 このレポートは、世界の心筋梗塞治療薬市場に関する詳細かつ包括的な分析の結果です。定量的分析と定性的分析データが、メーカー別、地域別、国別、種類別、用途別に記載されています。 市場は常に変化しているため、本レポートでは、競争、需要と供給の傾向、および多くの市場にわたる需要の変化に影響する主要な要因を調査しました。主要な競合他社の企業概要と製品例、および2023年の市場シェア予測も記載しました。 本レポートの主な目的は次のとおりです。 - 世界および主要国の市場機会の規模を決定するため - 心筋梗塞治療薬の成長可能性を評価するため - 各製品および最終用途市場の将来の成長を予測するため - 市場に影響を与える競争要因を評価するため 心筋梗塞治療薬市場は種類と用途によって区分されます。2018年～2029年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。 種類別セグメント ・抗血小板薬、抗凝固薬、β遮断薬、スタチン薬、その他 用途別セグメント ・病院、診療所、その他 主要な市場プレーヤー ・Bayer、Pfizer、Astrazeneca、Novartis、Boehringer Ingelheim、Daiichi Sankyo、Johnson & Johnson、Merck、Sanofi 地域別セグメントは次の地域・国をカバーします。 ・北米（米国、カナダ、メキシコ） ・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア） ・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア） ・南アメリカ（ブラジル、アルゼンチン、コロンビア） ・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ） 本調査レポートの内容は計15章あります。 ・第1章では、心筋梗塞治療薬製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。 ・第2章では、主要な心筋梗塞治療薬メーカーの企業概要、2019年～2022年までの心筋梗塞治療薬の価格、販売量、売上、市場シェアを掲載しています。 ・第3章では、主要な心筋梗塞治療薬メーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。 ・第4章では、2018年～2029年までの地域別心筋梗塞治療薬の販売量、売上、成長性を示しています。 ・第5、6章では、2018年～2029年までの心筋梗塞治療薬の種類別と用途別の市場規模、市場シェアと成長率を掲載しています。 ・第7、8、9、10、11章では、2018年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2029年までの主要地域での心筋梗塞治療薬市場予測を収録しています。 ・第12章では、市場力学、成長要因、阻害要因、トレンド、ポーターズファイブフォース分析、新型コロナウイルス感染症とロシア・ウクライナ戦争の影響を掲載しています。 ・第13章では、主要な原材料、主要なサプライヤー、および心筋梗塞治療薬の産業チェーンを掲載しています。 ・第14、15章では、心筋梗塞治療薬の販売チャネル、販売業者、顧客、調査結果について説明します。 ***** 目次(一部) ***** ・市場概要 - 心筋梗塞治療薬の概要 - 種類別分析（2018年vs2022年vs2029年）：抗血小板薬、抗凝固薬、β遮断薬、スタチン薬、その他 - 用途別分析（2018年vs2022年vs2029年）：病院、診療所、その他 - 世界の心筋梗塞治療薬市場規模・予測 - 世界の心筋梗塞治療薬生産能力分析 - 市場の成長要因・阻害要因・動向 ・メーカー情報（企業概要、製品概要、販売量、価格、売上） - Bayer、Pfizer、Astrazeneca、Novartis、Boehringer Ingelheim、Daiichi Sankyo、Johnson & Johnson、Merck、Sanofi ・メーカー別市場シェア・市場集中度 ・地域別市場分析2018年-2029年 ・種類別分析2018年-2029年：抗血小板薬、抗凝固薬、β遮断薬、スタチン薬、その他 ・用途別分析2018年-2029年：病院、診療所、その他 ・心筋梗塞治療薬の北米市場 - 種類別市場規模2018年-2029年 - 用途別市場規模2018年-2029年 - 主要国別市場規模：アメリカ、カナダ、メキシコなど ・心筋梗塞治療薬のヨーロッパ市場 - 種類別市場規模2018年-2029年 - 用途別市場規模2018年-2029年 - 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど ・心筋梗塞治療薬のアジア市場 - 種類別市場規模2018年-2029年 - 用途別市場規模2018年-2029年 - 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど ・心筋梗塞治療薬の南米市場 - 種類別市場規模2018年-2029年 - 用途別市場規模2018年-2029年 - 主要国別市場規模：ブラジル、アルゼンチンなど ・心筋梗塞治療薬の中東・アフリカ市場 - 種類別市場規模2018年-2029年 - 用途別市場規模2018年-2029年 - 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど ・市場力学（成長要因、阻害要因、トレンド、ポーターズファイブフォース分析） ・原材料および産業チェーン ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
According to our (Global Info Research) latest study, the global Drugs for Myocardial Infarction market size was valued at USD 1380.9 million in 2022 and is forecast to a readjusted size of USD 2257.3 million by 2029 with a CAGR of 7.3% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The treatment of myocardial infarction (heart attack) typically involves a combination of medications to alleviate symptoms, prevent further damage to the heart, and improve long-term outcomes.
This report is a detailed and comprehensive analysis for global Drugs for Myocardial Infarction market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Drugs for Myocardial Infarction market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Drugs for Myocardial Infarction market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Drugs for Myocardial Infarction market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Drugs for Myocardial Infarction market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Drugs for Myocardial Infarction
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Drugs for Myocardial Infarction market based on the following parameters – company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Bayer, Pfizer, Astrazeneca, Novartis and Boehringer Ingelheim, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market Segmentation
Drugs for Myocardial Infarction market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Antiplatelet Drugs
Anticoagulants
Beta-blockers
Statin Drugs
Other
Market segment by Application
Hospital
Clinic
Other
Major players covered
Bayer
Pfizer
Astrazeneca
Novartis
Boehringer Ingelheim
Daiichi Sankyo
Johnson & Johnson
Merck
Sanofi
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Drugs for Myocardial Infarction product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Drugs for Myocardial Infarction, with price, sales, revenue and global market share of Drugs for Myocardial Infarction from 2018 to 2023.
Chapter 3, the Drugs for Myocardial Infarction competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Drugs for Myocardial Infarction breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Drugs for Myocardial Infarction market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Drugs for Myocardial Infarction.
Chapter 14 and 15, to describe Drugs for Myocardial Infarction sales channel, distributors, customers, research findings and conclusion.
1 Market Overview
1.1 Product Overview and Scope of Drugs for Myocardial Infarction
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Drugs for Myocardial Infarction Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 Antiplatelet Drugs
1.3.3 Anticoagulants
1.3.4 Beta-blockers
1.3.5 Statin Drugs
1.3.6 Other
1.4 Market Analysis by Application
1.4.1 Overview: Global Drugs for Myocardial Infarction Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Hospital
1.4.3 Clinic
1.4.4 Other
1.5 Global Drugs for Myocardial Infarction Market Size & Forecast
1.5.1 Global Drugs for Myocardial Infarction Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Drugs for Myocardial Infarction Sales Quantity (2018-2029)
1.5.3 Global Drugs for Myocardial Infarction Average Price (2018-2029)
2 Manufacturers Profiles
2.1 Bayer
2.1.1 Bayer Details
2.1.2 Bayer Major Business
2.1.3 Bayer Drugs for Myocardial Infarction Product and Services
2.1.4 Bayer Drugs for Myocardial Infarction Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Bayer Recent Developments/Updates
2.2 Pfizer
2.2.1 Pfizer Details
2.2.2 Pfizer Major Business
2.2.3 Pfizer Drugs for Myocardial Infarction Product and Services
2.2.4 Pfizer Drugs for Myocardial Infarction Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Pfizer Recent Developments/Updates
2.3 Astrazeneca
2.3.1 Astrazeneca Details
2.3.2 Astrazeneca Major Business
2.3.3 Astrazeneca Drugs for Myocardial Infarction Product and Services
2.3.4 Astrazeneca Drugs for Myocardial Infarction Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Astrazeneca Recent Developments/Updates
2.4 Novartis
2.4.1 Novartis Details
2.4.2 Novartis Major Business
2.4.3 Novartis Drugs for Myocardial Infarction Product and Services
2.4.4 Novartis Drugs for Myocardial Infarction Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Novartis Recent Developments/Updates
2.5 Boehringer Ingelheim
2.5.1 Boehringer Ingelheim Details
2.5.2 Boehringer Ingelheim Major Business
2.5.3 Boehringer Ingelheim Drugs for Myocardial Infarction Product and Services
2.5.4 Boehringer Ingelheim Drugs for Myocardial Infarction Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Boehringer Ingelheim Recent Developments/Updates
2.6 Daiichi Sankyo
2.6.1 Daiichi Sankyo Details
2.6.2 Daiichi Sankyo Major Business
2.6.3 Daiichi Sankyo Drugs for Myocardial Infarction Product and Services
2.6.4 Daiichi Sankyo Drugs for Myocardial Infarction Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Daiichi Sankyo Recent Developments/Updates
2.7 Johnson & Johnson
2.7.1 Johnson & Johnson Details
2.7.2 Johnson & Johnson Major Business
2.7.3 Johnson & Johnson Drugs for Myocardial Infarction Product and Services
2.7.4 Johnson & Johnson Drugs for Myocardial Infarction Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Johnson & Johnson Recent Developments/Updates
2.8 Merck
2.8.1 Merck Details
2.8.2 Merck Major Business
2.8.3 Merck Drugs for Myocardial Infarction Product and Services
2.8.4 Merck Drugs for Myocardial Infarction Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Merck Recent Developments/Updates
2.9 Sanofi
2.9.1 Sanofi Details
2.9.2 Sanofi Major Business
2.9.3 Sanofi Drugs for Myocardial Infarction Product and Services
2.9.4 Sanofi Drugs for Myocardial Infarction Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Sanofi Recent Developments/Updates
3 Competitive Environment: Drugs for Myocardial Infarction by Manufacturer
3.1 Global Drugs for Myocardial Infarction Sales Quantity by Manufacturer (2018-2023)
3.2 Global Drugs for Myocardial Infarction Revenue by Manufacturer (2018-2023)
3.3 Global Drugs for Myocardial Infarction Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Drugs for Myocardial Infarction by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Drugs for Myocardial Infarction Manufacturer Market Share in 2022
3.4.2 Top 6 Drugs for Myocardial Infarction Manufacturer Market Share in 2022
3.5 Drugs for Myocardial Infarction Market: Overall Company Footprint Analysis
3.5.1 Drugs for Myocardial Infarction Market: Region Footprint
3.5.2 Drugs for Myocardial Infarction Market: Company Product Type Footprint
3.5.3 Drugs for Myocardial Infarction Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Drugs for Myocardial Infarction Market Size by Region
4.1.1 Global Drugs for Myocardial Infarction Sales Quantity by Region (2018-2029)
4.1.2 Global Drugs for Myocardial Infarction Consumption Value by Region (2018-2029)
4.1.3 Global Drugs for Myocardial Infarction Average Price by Region (2018-2029)
4.2 North America Drugs for Myocardial Infarction Consumption Value (2018-2029)
4.3 Europe Drugs for Myocardial Infarction Consumption Value (2018-2029)
4.4 Asia-Pacific Drugs for Myocardial Infarction Consumption Value (2018-2029)
4.5 South America Drugs for Myocardial Infarction Consumption Value (2018-2029)
4.6 Middle East and Africa Drugs for Myocardial Infarction Consumption Value (2018-2029)
5 Market Segment by Type
5.1 Global Drugs for Myocardial Infarction Sales Quantity by Type (2018-2029)
5.2 Global Drugs for Myocardial Infarction Consumption Value by Type (2018-2029)
5.3 Global Drugs for Myocardial Infarction Average Price by Type (2018-2029)
6 Market Segment by Application
6.1 Global Drugs for Myocardial Infarction Sales Quantity by Application (2018-2029)
6.2 Global Drugs for Myocardial Infarction Consumption Value by Application (2018-2029)
6.3 Global Drugs for Myocardial Infarction Average Price by Application (2018-2029)
7 North America
7.1 North America Drugs for Myocardial Infarction Sales Quantity by Type (2018-2029)
7.2 North America Drugs for Myocardial Infarction Sales Quantity by Application (2018-2029)
7.3 North America Drugs for Myocardial Infarction Market Size by Country
7.3.1 North America Drugs for Myocardial Infarction Sales Quantity by Country (2018-2029)
7.3.2 North America Drugs for Myocardial Infarction Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 Europe
8.1 Europe Drugs for Myocardial Infarction Sales Quantity by Type (2018-2029)
8.2 Europe Drugs for Myocardial Infarction Sales Quantity by Application (2018-2029)
8.3 Europe Drugs for Myocardial Infarction Market Size by Country
8.3.1 Europe Drugs for Myocardial Infarction Sales Quantity by Country (2018-2029)
8.3.2 Europe Drugs for Myocardial Infarction Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 Asia-Pacific
9.1 Asia-Pacific Drugs for Myocardial Infarction Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Drugs for Myocardial Infarction Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Drugs for Myocardial Infarction Market Size by Region
9.3.1 Asia-Pacific Drugs for Myocardial Infarction Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Drugs for Myocardial Infarction Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 South America
10.1 South America Drugs for Myocardial Infarction Sales Quantity by Type (2018-2029)
10.2 South America Drugs for Myocardial Infarction Sales Quantity by Application (2018-2029)
10.3 South America Drugs for Myocardial Infarction Market Size by Country
10.3.1 South America Drugs for Myocardial Infarction Sales Quantity by Country (2018-2029)
10.3.2 South America Drugs for Myocardial Infarction Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 Middle East & Africa
11.1 Middle East & Africa Drugs for Myocardial Infarction Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Drugs for Myocardial Infarction Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Drugs for Myocardial Infarction Market Size by Country
11.3.1 Middle East & Africa Drugs for Myocardial Infarction Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Drugs for Myocardial Infarction Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 Market Dynamics
12.1 Drugs for Myocardial Infarction Market Drivers
12.2 Drugs for Myocardial Infarction Market Restraints
12.3 Drugs for Myocardial Infarction Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 Raw Material and Industry Chain
13.1 Raw Material of Drugs for Myocardial Infarction and Key Manufacturers
13.2 Manufacturing Costs Percentage of Drugs for Myocardial Infarction
13.3 Drugs for Myocardial Infarction Production Process
13.4 Drugs for Myocardial Infarction Industrial Chain
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Drugs for Myocardial Infarction Typical Distributors
14.3 Drugs for Myocardial Infarction Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer